FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 330:1560-1564 June 2, 1994 Number 22 Next

	Full Text Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article PubMed Citation

ABSTRACT

Background Most patients with chronic idiopathic thrombocytopenic purpura have a response to corticosteroids or intravenous immune globulin, but improvement is often transitory. Splenectomy may provide only a short-term benefit. Because pulsed high-dose therapy with potent synthetic corticosteroids is inexpensive, well tolerated, and effective in patients with secretory B-cell neoplasms, a similar regimen was examined for its efficacy in patients with chronic idiopathic thrombocytopenic purpura that was resistant to other treatments.

Methods Ten consecutively referred patients who had persistent symptomatic idiopathic thrombocytopenic purpura after undergoing at least two standard therapies were treated with six cycles of dexamethasone (40 mg per day for 4 sequential days every 28 days).

Results All patients had increased platelet counts (mean [±SD] count before treatment, 12,000 ±8200 per cubic millimeter; after treatment, 248,000 ±130,000 per cubic millimeter). The platelet counts remained above 100,000 per cubic millimeter for at least six months after the last cycle of treatment. There were no serious side effects. Features of hyperadrenocorticism due to prior corticosteroid therapy resolved during treatment. The cost of the drug was approximately $100 per patient.

Conclusions Although the possibility of spontaneous remission and a delayed benefit from prior therapy cannot be excluded in this small group of patients, pulsed high-dose treatment with dexamethasone may provide a low-cost therapeutic option with minimal side effects in patients with refractory idiopathic thrombocytopenic purpura.

Source Information

From the Divison of Hematology and Oncology, Department of Internal Medicine, Wayne State University School of Medicine and Harper Hospital, Detroit.

Address reprint requests to Dr. Andersen at 403 Violet S., Harper Hospital, 3990 John R St., Detroit, MI 48201.

Full Text of this Article

Related Letters:

High-Dose Pulsed Dexamethasone for Immune Thrombocytopenia
Demiroglu H., Dündar S., Andersen J. C.
Extract | Full Text  
N Engl J Med 1997; 337:425-427, Aug 7, 1997. Correspondence

This article has been cited by other articles:

• Rodeghiero, F., Stasi, R., Gernsheimer, T., Michel, M., Provan, D., Arnold, D. M., Bussel, J. B., Cines, D. B., Chong, B. H., Cooper, N., Godeau, B., Lechner, K., Mazzucconi, M. G., McMillan, R., Sanz, M. A., Imbach, P., Blanchette, V., Kuhne, T., Ruggeri, M., George, J. N. (2009). Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood 113: 2386-2393 [Abstract] [Full Text]  
• Burzynski, J. (2009). New options after first-line therapy for chronic immune thrombocytopenic purpura. Am J Health Syst Pharm 66: S11-S21 [Abstract] [Full Text]  
• Mazzucconi, M. G., Fazi, P., Bernasconi, S., De Rossi, G., Leone, G., Gugliotta, L., Vianelli, N., Avvisati, G., Rodeghiero, F., Amendola, A., Baronci, C., Carbone, C., Quattrin, S., Fioritoni, G., D'Alfonso, G., Mandelli, F., for the Gruppo Italiano Malattie EMatologiche dell, (2007). Therapy with high-dose dexamethasone (HD-DXM) in previously untreated patients affected by idiopathic thrombocytopenic purpura: a GIMEMA experience. Blood 109: 1401-1407 [Abstract] [Full Text]  
• Stasi, R., Provan, D. (2004). Management of Immune Thrombocytopenic Purpura in Adults. Mayo Clin Proc. 79: 504-522 [Abstract]  
• Vesely, S. K., Perdue, J. J., Rizvi, M. A., Terrell, D. R., George, J. N. (2004). Management of Adult Patients with Persistent Idiopathic Thrombocytopenic Purpura Following Splenectomy: A Systematic Review. ANN INTERN MED 140: 112-120 [Abstract] [Full Text]  
• Cheng, Y., Wong, R. S.M., Soo, Y. O.Y., Chui, C. H., Lau, F. Y., Chan, N. P.H., Wong, W. S., Cheng, G. (2003). Initial Treatment of Immune Thrombocytopenic Purpura with High-Dose Dexamethasone. NEJM 349: 831-836 [Abstract] [Full Text]  
• George, J. N., Vesely, S. K. (2003). Immune Thrombocytopenic Purpura -- Let the Treatment Fit the Patient. NEJM 349: 903-905 [Full Text]  
• Khouri, I., Tuan, B., Grant, K., Bleesing, J. J.H., Fleisher, T. A., McCarthy, L. J., Dzik, W., Cines, D. B., Blanchette, V. S. (2002). Immune Thrombocytopenic Purpura. NEJM 347: 449-450 [Full Text]  
• Gomez, F., Ruiz, P., Lopez, R., Rivera, C. (2002). Treatment with Megestrol Acetate Improves Human Immunodeficiency Virus-Associated Immune Thrombocytopenia. CVI 9: 583-587 [Abstract] [Full Text]  
• Galindo, M., Khamashta, M. A., Hughes, G. R. V. (1999). Splenectomy for refractory thrombocytopenia in the antiphospholipid syndrome. Rheumatology (Oxford) 38: 848-853 [Abstract] [Full Text]  
• Nomura, S., Matsuzaki, T., Ozaki, Y., Yamaoka, M., Yoshimura, C., Katsura, K., Xie, G. L., Kagawa, H., Ishida, T., Fukuhara, S. (1998). Clinical Significance of HLA-DRB1*0410 in Japanese Patients With Idiopathic Thrombocytopenic Purpura. Blood 91: 3616-3622 [Abstract] [Full Text]  
• Demiroglu, H., Dundar, S., Andersen, J. C. (1997). High-Dose Pulsed Dexamethasone for Immune Thrombocytopenia. NEJM 337: 425-427 [Full Text]  
• George, J. N., El-Harake, M. A., Raskob, G. E. (1994). Chronic Idiopathic Thrombocytopenic Purpura. NEJM 331: 1207-1211 [Full Text]  
• (1994). PULSED STEROIDS FOR ITP. JWatch General 1994: 1-1 [Full Text]  
• Schwartz, R. S. (1994). Treating Chronic Idiopathic Thrombocytopenic Purpura -- A New Application of an Old Treatment. NEJM 330: 1609-1610 [Full Text]